Last updated on February 2020

A Multiple-dose Study of ASP8374 an Immune Checkpoint Inhibitor as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors


Brief description of study

The primary purpose of this study is to evaluate the tolerability and safety profile of ASP8374 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumor malignancies. Also primary purpose is to characterize the pharmacokinetic profile of ASP8374 when administered as a single agent and in combination with pembrolizumab. Last primary purpose of this study is to determine the recommended Phase 2 dose (RP2D) of ASP8374 when administered as a single agent and in combination with pembrolizumab.

The secondary purpose of this study is to evaluate the anti-tumor effect (objective response rate [ORR], duration of response [DOR], persistence of response after discontinuation, and disease control rate [DCR]) of ASP8374 when administered as a single agent and in combination with pembrolizumab.

Detailed Study Description

This is a multi-center, multiple-dose, dose-escalation and expansion study of ASP8374 as a single agent and in combination with pembrolizumab. After discontinuation of study drug treatment, all participants will complete an end of treatment visit and safety follow-up visits. Participants will be enrolled in respectively escalation cohorts or expansion cohorts.

Escalation cohorts: Approximately 63 participants may be enrolled in the escalation cohorts (approximately 33 participants for monotherapy and 30 participants for combination therapy).

Expansion cohorts: The total number of subjects in the expansion cohorts will depend on the observed pharmacokinetic and antitumor activity. It is estimated that approximately 300 participants may be enrolled in the monotherapy and combination therapy expansion cohorts.

As the number of participants in the escalation cohorts and the expansion cohorts will depend on the observed Dose Limiting Toxicity (DLT), pharmacokinetics and antitumor activity, approximately 363 participants are expected to be enrolled.

Clinical Study Identifier: NCT03260322

Find a site near you

Start Over

Honor Health Research Institute

Scottsdale, AZ United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Fox Chase Cancer Center

Philadelphia, PA United States
  Connect »

Virginia Cancer Specialists

Fairfax, VA United States
  Connect »

Site CA15004

Edmonton, AB Canada
  Connect »

Site CA15003

Toronto, ON Canada
  Connect »

Site CA15001

Toronto, ON Canada
  Connect »

Site CA15002

Montreal, QC Canada
  Connect »

Site KR82004

Goyang-si, Korea, Republic of
  Connect »

Site KR82005

Seongnam-Si, Korea, Republic of
  Connect »

Site KR82001

Seoul, Korea, Republic of
  Connect »

SIte KR82002

Seoul, Korea, Republic of
  Connect »

Site TW88602

Taichung, Taiwan
  Connect »

University of California, Davis

Sacramento, CA United States
  Connect »

Henry Ford Health System

Detroit, MI United States
  Connect »

Site KR82006

Seoul, Korea, Republic of
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Site ES34003

Barcelona, Spain
  Connect »

Site TW88603

Taipei City, Taiwan
  Connect »

Site GB44006

London, United Kingdom
  Connect »

Site GB44005

Sutton Surry, United Kingdom
  Connect »

University of Arizona

Tucson, AZ United States
  Connect »

Cedars-Sinai Medical Center

Los Angeles, CA United States
  Connect »

University of North Carolina

Chapel Hill, NC United States
  Connect »

Site ES34010

Barcelona, Spain
  Connect »

Site GB44003

London, United Kingdom
  Connect »

Site GB44004

Newcastle upon Tyne, United Kingdom
  Connect »

Site PT35106

Porto, Portugal
  Connect »

Site ES34002

Barcelona, Spain
  Connect »

Site ES34009

Barcelona, Spain
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »

Site ES34014

Valencia, Spain
  Connect »

Site GB44001

Leeds, United Kingdom
  Connect »

Site PT35101

Lisboa, Portugal
  Connect »